Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Cash from Financing Activities for 9 consecutive years, with -$54000.0 as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities fell 31.71% year-over-year to -$54000.0; the TTM value through Mar 2026 reached -$144000.0, down 100.03%, while the annual FY2025 figure was -$131000.0, 100.03% down from the prior year.
  • Cash from Financing Activities hit -$54000.0 in Q1 2026 for Bicycle Therapeutics, down from -$15000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $549.6 million in Q2 2024 and bottomed at -$31.9 million in Q3 2024.
  • Average Cash from Financing Activities over 5 years is $45.7 million, with a median of $203000.0 recorded in 2024.
  • Year-over-year, Cash from Financing Activities surged 147466.67% in 2023 and then tumbled 113.61% in 2024.
  • Bicycle Therapeutics' Cash from Financing Activities stood at $5.9 million in 2022, then plummeted by 93.44% to $386000.0 in 2023, then tumbled by 47.41% to $203000.0 in 2024, then plummeted by 107.39% to -$15000.0 in 2025, then tumbled by 260.0% to -$54000.0 in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at -$54000.0, -$15000.0, and -$30000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.